In a clinical trial, there were no significant differences in the number of complications between Eleview® and normal saline with methylene blue (the comparator arm).1,2

Eleview® is safe and well tolerated
Complication Eleview®
n (%)
Saline with methylene 
blue n (%)
Subjects with at least one complication 17 (15.0) 17 (15.2)
Intraprocedural bleeding 8 (7.1) 11 (9.8)
Early (<24 h) and delayed (>24 h)
post-EMR bleeding
2 (1.8) 1 (0.9)
Post-procedural bleeding 0 (0.0) 1 (0.9)
Perforation 0 (0.0) 1 (0.9)
Post-polypectomy syndrome 6 (5.3) 3 (2.7)
Hospital admissions for any
post-procedural clinically relevant complication
1 (0.9) 0 (0.0)
% calculated on n subjects in safety set.

NOTE: This data is interim until final patient analysis is completed after the 60-day post-procedure follow-up period.

Receive the latest news and events

Get Eleview® product updates, Aries news, and alerts for events both online and in your area. Register for updates

Box of Eleview® with ampoules

Study design

View details of the Eleview® study design: Endoscopic removal of polyps in the gastrointestinal tract: A randomized, double-blind, comparative effectiveness and safety study of Eleview® for EMR of large sessile polyps in the colon.

Less volume and fewer reinjections with Eleview®

Designed to require fewer reinjections, which may lead to better safety2

  • Eleview® is designed to require fewer reinjections and less volume for resections2

INDICATIONS FOR USE

Eleview® submucosal injectable composition is intended for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions, prior to excision with a snare or endoscopic device.

CONTRAINDICATIONS

Patients with known sensitivity to any of the components contained in Eleview®.

WARNINGS AND PRECAUTIONS

  • The endoscopist injecting Eleview® must be experienced in the administration technique.
  • The safety of Eleview® has not been established in pregnant or lactating women, or in children under 18 years of age.
  • Eleview® is provided in single-use ampoules. Eleview® should not be reused after the first opening. Any emulsion not injected during the procedure should not be reused for another endoscopic procedure.
  • Do not use if the primary packaging (ampoule) or secondary packaging (aluminum pouch) is damaged.
  • Do not use if the twist-off cap is damaged.
  • Do not use if the emulsion is not clear, shows any signs of opalescence, or contains floating or precipitated visible particles.
  • The product compatibility with other substances has not been tested.

ADVERSE REACTIONS

Rarely, local bleeding and/or inflammatory reaction could occur which may or may not be associated with Eleview®.

DOSAGE AND ADMINISTRATION

The administered dose of Eleview® should be determined based on the dimensions of the lesion to be removed. Inject into the submucosa the amount of Eleview® needed to form a submucosal cushion of optimal height and shape for the lesion to be removed. During the procedure do not exceed a total dose of 50 mL per patient, either in single or in multiple administrations.

Please see Instructions for Use for complete Important Safety Information.